Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

US9834595B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9834595-B2
Application numberUS-201514926381-A
CountryUS
Kind codeB2
Filing dateOct 29, 2015
Priority dateJun 5, 2008
Publication dateDec 5, 2017
Grant dateDec 5, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for the neutralization of RSV, comprising administering, to a subject in need thereof, a multivalent polypeptide comprising two or more immunoglobulin single variable domains that specifically binds to an F protein of a respiratory syncytial virus (RSV), wherein the immunoglobulin single variable domains comprise: a CDR1 comprising the amino acid sequence of SEQ ID NO: 2595; a CDR2 comprising the amino acid sequence of SEQ ID NO: 2611; a CDR3 comprising the amino acid sequence of SEQ ID NO: 2627; and/or administering to the subject a pharmaceutical composition comprising the multivalent polypeptide. 2. The method according to claim 1 , wherein the immunoglobulin single variable domain is a domain antibody, a single domain antibody, a VHH sequence, a partially or fully humanized VHH sequence, or a camelized VH sequence. 3. The method according to claim 1 , wherein the single variable domains comprise one or more amino acid sequences having at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NOs: 1 to 22, 126 to 407, 2431 to 2448, 2574 to 2581, 2682 to 2717 and 3064 to 3128 in which for the purposes of determining the degree of amino acid identity, the amino acid residues that form the CDR sequences are disregarded; and in which optionally one or more of the amino acid residues at positions 11, 37, 44, 45, 47, 83, 84, 103, 104 and 108 according to the Kabat numbering are chosen from the Hallmark residues mentioned in Table B-2. 4. The method according to claim 1 , wherein the polypeptide comprises two or more immunoglobulin single variable domains selected from SEQ ID NOs: 372, 2579, or 2999 to 3015. 5. The method according to claim 1 , wherein the immunoglobulin single variable domain is a partially or fully humanized VHH sequence. 6. The method according to claim 1 , wherein the polypeptide further comprises one or more other groups, residues, moieties or binding units selected from the group consisting of a domain antibody, a single domain antibody, a VHH sequence, a partially or fully humanized VHH sequence, a camelized VH sequence or an immunoglobulin single variable domain. 7. The method according to claim 1 , wherein the polypeptide comprises three immunoglobulin single variable domains. 8. The method according to claim 1 , wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2395, 2415, 2989 to 2994, 2996 to 2998, 3029, and 3049 to 3055. 9. The method according to claim 1 , wherein the multivalent polypeptide and/or composition comprising the multivalent polypeptide is administered to the pulmonary tissue of the subject. 10. The method according to claim 9 , wherein the multivalent polypeptide and/or composition comprising the multivalent polypeptide is administered by use of an inhaler, an intranasal delivery device or an aerosol.

Assignees

Inventors

Classifications

  • Picornaviridae (F), e.g. hepatitis A virus · CPC title

  • Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV] · CPC title

  • C07K16/108Primary

    Orthomyxoviridae (F), e.g. influenza virus · CPC title

  • Comprising a combination of two or more separate antibodies · CPC title

  • Hinge · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9834595B2 cover?
The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
Who is the assignee on this patent?
Ablynx Nv
What technology area does this patent fall under?
Primary CPC classification C07K16/108. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Dec 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).